Investor Relations
Jul 16, 2018
OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada MORE >>
Jun 11, 2018
OPKO Health Completes Enrollment in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes and Obesity MORE >>
May 18, 2018
OPKO Plans to Address Draft Local Coverage Determination Published by Novitas Solutions for 4Kscore Test MORE >>
May 08, 2018
OPKO Health Reports First Quarter 2018 Financial Results MORE >>

Press Releases

All Releases
OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada
Jul 16, 2018

MIAMI , July 16, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced today that the Company’s partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has received approval from Health Canada to market RAYALDEE ® in Canada for the treatment of secondary hyperparathyroidism (SHPT) in

OPKO Health Completes Enrollment in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes and Obesity
Jun 11, 2018

MIAMI , June 11, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced it has completed enrollment of 110 subjects in a Phase 2b dose escalation trial of OPK88003 to treat type 2 diabetes and obesity.  OPK88003 is a once weekly injectable oxyntomodulin medicine with GLP-1 and

OPKO Plans to Address Draft Local Coverage Determination Published by Novitas Solutions for 4Kscore Test
May 18, 2018

MIAMI , May 18, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq:OPK) today announced that Novitas Solutions, Inc. issued a draft local coverage determination (LCD) for the 4Kscore test®. The draft LCD is a proposed non-coverage policy for the 4Kscore test for Medicare and, prior to its

OPKO Health Reports First Quarter 2018 Financial Results
May 08, 2018

Conference Call begins today at 4:30 p.m. Eastern Time MIAMI , May 08, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports financial results and business highlights for the three months ended March 31, 2018 . Financial Highlights Consolidated revenues for the three months ended March

OPKO Health to Announce First Quarter 2018 Financial Results on May 8, 2018
May 02, 2018

MIAMI , May 02, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to announce its operating and financial results for the three months ended March 31, 2018 after the close of the U.S. financial markets on Tuesday, May 8, 2018 . OPKO’s senior management will provide a business update and

OPKO Health Appoints Geoff Monk General Manager at BioReference Laboratories
May 01, 2018

MIAMI , May 01, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced the appointment of Geoff Monk as General Manager with overall responsibility for BioReference Laboratories (BRL), an OPKO Health company and the third largest clinical laboratory in the United States . Mr.

OPKO Health to Remain on the Tel Aviv Stock Exchange
Apr 27, 2018

MIAMI , April 27, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced today it intends to remain on the Tel Aviv Stock Exchange (TASE) and withdraw its request to voluntarily delist its common stock from the TASE.  The initial delisting request was made public by the Company in a Form

OPKO Health Enrolls First Patient in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes
Mar 23, 2018
MIAMI , March 23, 2018 (GLOBE NEWSWIRE) -- OPKO Health , Inc.  (NASDAQ:OPK) has enrolled the first patient in a Phase 2b dose escalation trial of OPK88003, a once-weekly oxyntomodulin therapy containing dual agonist activity towards GLP-1 and Glucagon receptors, to treat type 2 diabetes and
OPKO Health Announces Landmark Study Showing 4Kscore® Test is Strong Predictor of Prostate Cancer Mortality Published in European Urology
Mar 16, 2018
Study of 11,506 men shows that healthy men with an abnormal PSA and a low 4Kscore test result can be safely monitored rather than undergo prostate biopsy MIAMI , March 16, 2018 (GLOBE NEWSWIRE) --   OPKO Health, Inc. (NASDAQ:OPK) today announced that data from a landmark study of the 4Kscore® test
OPKO Health Reports 2017 Fourth Quarter Business Highlights and Financial Results
Mar 01, 2018
Conference Call begins today at 4:30 p.m. Eastern Time
OPKO Health to Announce Fourth Quarter and Year End 2017 Financial Results on March 1, 2018
Feb 26, 2018
MIAMI , Feb. 26, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), plans to announce its operating and financial results for the three and twelve months ended December 31, 2017 , after the close of the U.S. financial markets on Thursday, March 1, 2018 .
OPKO Health Announces Leadership Changes at BioReference Laboratories
Jan 26, 2018
MIAMI , Jan. 26, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), announces that Gregory Henderson , M.D., Ph.D., has resigned from his position as President of BioReference Laboratories , an OPKO Health company and the third largest commercial laboratory in the United States , effective
OPKO'S GeneDx Announces Research Collaboration with Radboud University Medical Center
Jan 12, 2018
Aimed at identifying novel genes and pathways to help manage human genetic diseases
OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy
Nov 27, 2017
Enlarged Prostate Affects Approximately 50 Million Men in the U.S.
OPKO Health Reports 2017 Third Quarter Highlights and Financial Results
Nov 08, 2017
RAYALDEE total prescriptions increased 66% in Q3 2017 compared with Q2 2017 4Kscore utilization increased 19% in Q3 2017 compared with Q3 2016 4Kscore TV ads in the Northeast to begin November 21 Submitted a Premarket Approval (PMA) application with FDA for Claros point-of-care (POC) prostate
OPKO Health Submits Premarket Approval Application with FDA for a Point-of-Care PSA Test with the Claros® 1 Platform
Nov 07, 2017
Addresses a $625 million U.S. market opportunity
OPKO Health to Announce 2017 Third Quarter Financial Results on November 8, 2017
Nov 03, 2017
MIAMI , Nov. 03, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to announce its operating and financial results for the three and nine months ended September 30, 2017 , after the close of the U.S. financial markets on Wednesday, November 8, 2017 .
OPKO Health Licensee TESARO Announces FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated with Chemotherapy
Oct 26, 2017
OPKO to receive tiered double-digit royalties on product sales
OPKO Health Enters into Exclusive Agreement with Japan Tobacco to Develop and Commercialize RAYALDEE® in Japan
Oct 12, 2017
OPKO to receive up to $118 million in upfront and milestone payments, plus tiered double-digit royalties on product sales
OPKO's BioReference Laboratories and The Garage Announce National Strategic Affiliation to Enhance Value-Based Care
Sep 19, 2017
Providing clinicians with advanced tools to guide quality, value-based care; affiliation to be showcased during the NAACOS Fall 2017 Conference in Washington, DC from Oct. 4-6
Displaying 1 - 20 of 355